Analysts Set UnitedHealth Group Inc (UNH) PT at $226.08

UnitedHealth Group Inc (NYSE:UNH) has received an average recommendation of “Buy” from the twenty-eight analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and twenty-five have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $226.08.

A number of equities research analysts recently issued reports on the company. Goldman Sachs Group assumed coverage on UnitedHealth Group in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $269.00 price objective on the stock. Credit Suisse Group restated a “buy” rating on shares of UnitedHealth Group in a research note on Wednesday, December 27th. Cantor Fitzgerald restated a “buy” rating and issued a $235.00 price objective on shares of UnitedHealth Group in a research note on Monday, December 25th. ValuEngine cut UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Raymond James Financial restated a “buy” rating on shares of UnitedHealth Group in a research note on Wednesday, December 6th.

UnitedHealth Group (NYSE UNH) traded up $1.19 during midday trading on Monday, hitting $225.39. The stock had a trading volume of 2,543,363 shares, compared to its average volume of 2,682,745. The company has a market cap of $217,920.00, a PE ratio of 25.61, a price-to-earnings-growth ratio of 1.57 and a beta of 0.66. UnitedHealth Group has a 12 month low of $156.09 and a 12 month high of $231.77. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.52.

UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 EPS for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.09. The company had revenue of $50.32 billion for the quarter, compared to analysts’ expectations of $50.38 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.50%. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.17 EPS. equities research analysts forecast that UnitedHealth Group will post 9.99 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Friday, December 1st were issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend was Thursday, November 30th. UnitedHealth Group’s payout ratio is presently 34.09%.

In other news, insider Thomas E. Roos sold 975 shares of the business’s stock in a transaction dated Thursday, October 19th. The stock was sold at an average price of $205.47, for a total transaction of $200,333.25. Following the completion of the transaction, the insider now owns 24,630 shares of the company’s stock, valued at $5,060,726.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail R. Wilensky sold 5,600 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total value of $1,250,536.00. Following the transaction, the director now directly owns 61,137 shares of the company’s stock, valued at approximately $13,652,503.47. The disclosure for this sale can be found here. Insiders have sold a total of 34,630 shares of company stock valued at $7,669,416 in the last ninety days. Insiders own 0.89% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Blue Chip Partners Inc. bought a new stake in UnitedHealth Group in the 2nd quarter worth approximately $110,000. Bruderman Asset Management LLC bought a new stake in UnitedHealth Group in the 2nd quarter worth approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in UnitedHealth Group by 433.3% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock worth $119,000 after buying an additional 520 shares during the last quarter. BDO Wealth Advisors LLC bought a new stake in UnitedHealth Group in the 2nd quarter worth approximately $121,000. Finally, Acrospire Investment Management LLC lifted its position in UnitedHealth Group by 130.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock worth $131,000 after buying an additional 400 shares during the last quarter. 86.01% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://weekherald.com/2018/01/11/analysts-set-unitedhealth-group-inc-unh-pt-at-226-08.html.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply